Nalmefene in Alcohol Dependence and Borderline Personality Disorder
Launched by FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU · Apr 22, 2016
Trial Information
Current as of June 15, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Alcohol use disorder according to DSM 5
- • Borderline personality disorder according to DSM 5
- • CGI-BPD \> 3
- • Female have to use contraception
- Exclusion Criteria:
- • Other axis I disorders
- • Severe organic disorder
- • Pregnancy or breastfeeding
- • Allergy to Nalmefene
- • Subjects with Opioids use disorder or in treatment with opioid agonists
About Fundació Institut De Recerca De L'hospital De La Santa Creu I Sant Pau
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau is a leading biomedical research organization based in Barcelona, dedicated to advancing scientific knowledge and improving patient care. Affiliated with the prestigious Hospital de la Santa Creu i Sant Pau, the foundation focuses on translational research across various medical disciplines, fostering innovation through collaboration among researchers, clinicians, and industry partners. It aims to bridge the gap between laboratory discoveries and clinical applications, ultimately enhancing healthcare outcomes and contributing to the global understanding of diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
Patients applied
Trial Officials
Juan C Pascual, MD PhD
Principal Investigator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials